XML 48 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
A summary of the stock option activity under the Company's equity plans, and inducement awards for the year ended December 31, 2022 is as follows:
(number of shares in millions)Number
of
shares		Weighted
average
exercise
price		Weighted
average
remaining
contractual
life (years)
Options outstanding at December 31, 20211.4 $20.38 
Less:
Options exercised— 26.22 
Options canceled or expired(0.7)26.99 
Options outstanding at December 31, 20220.7 13.38 4.62
Options exercisable at December 31, 20220.4 13.38 4.62
Options vested and expected to vest0.7 $13.38 4.62
Schedule of Restricted Stock Units Activity
A summary of the RSU awards activity under the Company's equity plans and inducement awards, including PSU awards for the year ended December 31, 2022, is as follows:
2022
(number of shares in millions)Number
of
shares		Weighted
average
grant date
fair value
RSUs unvested and outstanding at December 31, 20213.1 $24.96 
RSUs granted2.3 25.78 
Less:
RSUs vested(1.2)25.32 
RSUs canceled(0.5)26.83 
RSUs unvested and outstanding at December 31, 20223.7 $25.08 
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows:
Years Ended December 31,Six-month Transition Period Ended December 31,Year Ended June 30,
(in millions)2022202120202020
Cost of testing revenue$1.7 $1.5 $0.6 $1.2 
Cost of other revenue— 0.1 0.1 0.3 
Research and development expense5.2 4.2 2.4 5.0 
Selling, general, and administrative expense31.2 30.5 11.8 18.7 
Total stock-based compensation expense$38.1 $36.3 $14.9 $25.2 
Schedule of Aggregate Intrinsic Value
The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:
(in millions)As of
December 31, 2022
Aggregate intrinsic value of options outstanding$0.8 
Aggregate intrinsic value of options fully vested0.4 
Aggregate intrinsic value of RSUs outstanding54.0 
Schedule of Intrinsic Value of Options Exercised
The total intrinsic value of options exercised was as follows:
Years Ended December 31,Six-month Transition Period Ended December 31,Year Ended June 30,
(in millions)2022202120202020
Total intrinsic value of options exercised$— $29.2 $0.5 $8.8 
Schedule of Shares Purchased and Compensation Expenses for ESPP Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the periods reported are as follows:
Years Ended December 31,Six-month Transition Period Ended December 31,Year Ended June 30,
(in millions)2022202120202020
Shares purchased under the plans0.3 0.2 0.1 0.3 
Plan compensation expense$1.9 $1.5 $0.6 $1.7 
Schedule of Valuation Assumptions for ESPP
The fair value of shares issued under the Amended and Restated 2012 Purchase Plan that was in effect for each period reported was calculated using the Black‑Scholes option-pricing model using the weighted-average assumptions below. Each of these inputs is subjective and its determination generally requires significant judgment.
Years Ended December 31,Six-month Transition Period Ended December 31,Year Ended June 30,
2022202120202020
Risk-free interest rate1.4%0.1%0.2%1.8%
Expected dividend yield—%—%—%—%
Expected life (in years)0.50.50.50.5
Expected volatility53%60%94%99%